NCT06016738Phase 3Active not recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Study sponsor: Olema Pharmaceuticals, Inc. · OLMA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-31Estimated
Enrollment · participants510Estimated
Source updated2026-08-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: 30 Jun 2026. After: 31 Oct 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview